CL2019002986A1 - Nuevo compuesto sólido cristalino clorhidrato de 3-fenil-4-propil-1-(piridin-2-il)-1h-pirazol-5-ol. - Google Patents

Nuevo compuesto sólido cristalino clorhidrato de 3-fenil-4-propil-1-(piridin-2-il)-1h-pirazol-5-ol.

Info

Publication number
CL2019002986A1
CL2019002986A1 CL2019002986A CL2019002986A CL2019002986A1 CL 2019002986 A1 CL2019002986 A1 CL 2019002986A1 CL 2019002986 A CL2019002986 A CL 2019002986A CL 2019002986 A CL2019002986 A CL 2019002986A CL 2019002986 A1 CL2019002986 A1 CL 2019002986A1
Authority
CL
Chile
Prior art keywords
pyrazol
pyridin
propyl
phenyl
hydrochloride
Prior art date
Application number
CL2019002986A
Other languages
English (en)
Inventor
Sung Hwan Moon
Soo Jin Lee
Sung Chan Lee
Original Assignee
Aptabio Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aptabio Therapeutics Inc filed Critical Aptabio Therapeutics Inc
Publication of CL2019002986A1 publication Critical patent/CL2019002986A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A UN NUEVO CLORHIDRATO CRISTALINO DE 3-fenil-4-propil-1- (piridin-2-il)-1Hpirazol-5-ol, UN MÉTODO PARA PREPARAR EL COMPUESTO, Y UNA COMPOSICIÓN FARMACÉUTICA QUE CONTIENE EL COMPUESTO COMO INGREDIENTE ACTIVO.
CL2019002986A 2017-04-20 2019-10-18 Nuevo compuesto sólido cristalino clorhidrato de 3-fenil-4-propil-1-(piridin-2-il)-1h-pirazol-5-ol. CL2019002986A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020170050924A KR101856444B1 (ko) 2017-04-20 2017-04-20 3-페닐-4-프로필-1-(피리딘-2-일)-1ｈ-피라졸-5-올 염산염의 신규 결정형 고체 화합물

Publications (1)

Publication Number Publication Date
CL2019002986A1 true CL2019002986A1 (es) 2020-01-24

Family

ID=62184173

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2019002986A CL2019002986A1 (es) 2017-04-20 2019-10-18 Nuevo compuesto sólido cristalino clorhidrato de 3-fenil-4-propil-1-(piridin-2-il)-1h-pirazol-5-ol.

Country Status (14)

Country Link
US (1) US11174240B2 (es)
EP (1) EP3613733B1 (es)
JP (1) JP6982097B2 (es)
KR (1) KR101856444B1 (es)
CN (1) CN110678455B (es)
AU (1) AU2018256259B2 (es)
CA (1) CA3060046C (es)
CL (1) CL2019002986A1 (es)
CO (1) CO2019011547A2 (es)
ES (1) ES2924798T3 (es)
MX (1) MX2019012454A (es)
PL (1) PL3613733T3 (es)
RU (2) RU2021116820A (es)
WO (1) WO2018194416A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101840702B1 (ko) * 2017-11-01 2018-03-22 압타바이오 주식회사 간질환 치료제
KR102191180B1 (ko) * 2019-05-31 2020-12-15 삼진제약주식회사 안질환 치료용 조성물
US20230025836A1 (en) * 2019-11-21 2023-01-26 Samjin Pharmaceutical Co., Ltd. Eye drop composition for preventing or treating eye disease
US20230201179A1 (en) * 2020-04-08 2023-06-29 Aptabio Therapeutics Inc. Agent for treating contrast-induced acute kidney injury
KR102308991B1 (ko) * 2020-04-08 2021-10-06 압타바이오 주식회사 조영제 유발 급성 신부전 치료제
EP4137134A4 (en) * 2020-04-13 2024-08-07 Aptabio Therapeutics Inc MEDICATION AGAINST PULMONARY FIBROSIS WITH PYRAZOLE DERIVATIVE

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO179282C (no) * 1991-01-18 1996-09-11 Rhone Poulenc Agrochimie Nye 1-(2-pyridyl)pyrazolforbindelser til kontroll av skadeinsekter
KR20020071931A (ko) 2000-01-07 2002-09-13 트렌스폼 파마수티컬스 인코퍼레이티드 다양한 고체-형태들의 고도의 자료 처리 편성, 확인 및분석
WO2011028044A2 (ko) 2009-09-02 2011-03-10 이화여자대학교 산학협력단 피라졸 유도체, 이의 제조방법 및 이를 포함하는 골다공증 예방 및 치료용 조성물
WO2011028043A2 (ko) * 2009-09-02 2011-03-10 이화여자대학교 산학협력단 피라졸 유도체, 이의 제조방법 및 이를 포함하는 골다공증 예방 및 치료용 조성물
KR20120098462A (ko) * 2011-02-28 2012-09-05 이화여자대학교 산학협력단 피라졸 유도체, 이의 제조방법 및 이를 포함하는 골다공증 예방 및 치료용 조성물
KR20120098489A (ko) * 2011-02-28 2012-09-05 이화여자대학교 산학협력단 피라졸 유도체를 포함하는 심혈관 질환 예방 및 치료용 조성물
KR101633957B1 (ko) * 2012-08-27 2016-06-27 이화여자대학교 산학협력단 피라졸 유도체를 포함하는 신장질환 예방 또는 치료용 조성물
TW201603849A (zh) 2014-07-01 2016-02-01 賽諾菲公司 響片配置及其藥物輸送裝置

Also Published As

Publication number Publication date
RU2019132946A3 (es) 2021-04-19
EP3613733A1 (en) 2020-02-26
US11174240B2 (en) 2021-11-16
CA3060046C (en) 2021-08-31
WO2018194416A1 (ko) 2018-10-25
JP6982097B2 (ja) 2021-12-17
BR112019022002A2 (pt) 2020-05-12
MX2019012454A (es) 2019-12-19
RU2021116820A (ru) 2021-06-22
CN110678455A (zh) 2020-01-10
CN110678455B (zh) 2022-08-16
AU2018256259A1 (en) 2019-11-07
JP2020517661A (ja) 2020-06-18
EP3613733B1 (en) 2022-07-20
PL3613733T3 (pl) 2022-09-26
CA3060046A1 (en) 2018-10-25
KR101856444B1 (ko) 2018-05-10
EP3613733A4 (en) 2020-11-18
RU2754255C2 (ru) 2021-08-31
RU2019132946A (ru) 2021-04-19
ES2924798T3 (es) 2022-10-11
CO2019011547A2 (es) 2020-02-18
AU2018256259B2 (en) 2020-06-18
US20210122726A1 (en) 2021-04-29

Similar Documents

Publication Publication Date Title
CL2019002986A1 (es) Nuevo compuesto sólido cristalino clorhidrato de 3-fenil-4-propil-1-(piridin-2-il)-1h-pirazol-5-ol.
CL2019001565A1 (es) Composición farmacéutica para prevenir o tratar el cáncer, comprendiendo el polímorfo cristalino del hexoxido tetraarsénico.
UY35663A (es) Derivados de piperidinil-indol como inhibidores del factor de complemento b y usos de los mismos
PH12018500591A1 (en) Heterocyclic compounds and uses thereof
NI201700011A (es) 2-(morfolin-4-il)-1,7-naftiridinas.
GT201300174A (es) Compuestos de indol o análogos de los mismos útiles para el tratamiento de la degeneración macular relacionada con la edad (dme)
NI201500135A (es) Composición farmacéutica de hidrocloruro de s-ketamina
CO2018000589A2 (es) Oxiesteroles y composiciones farmacéuticas que los contienen
MX2016000675A (es) Derivados de amino-metil-biarilo como inhibidores del factor de complemento d y usos de los mismos.
CU20160192A7 (es) Derivados de indano e indolina útiles como activadores de la guanilato ciclasa soluble
CR20140508A (es) Moduladores de la ruta del complemento y usos de los mismos
CU20130139A7 (es) Derivados glocósidos y usos de los mismos
CO2019002246A2 (es) Compuesto heterocíclico nitrogenado bicíclico
BR112017006085A2 (pt) compostos 1-alquil-6-oxo-1,6-di-hidropiridin-3-ila e uso como moduladores sgrm
DK3103453T3 (da) Medicinsk sammensætning omfattende heterocyklisk diamino-carboxamidforbindelse som aktiv bestanddel
BR112016001876A2 (pt) composto de benzoxaborol tricíclico, método de preparação e uso do mesmo
HK1243927A1 (zh) 含有茶皂醇衍生物作爲活性成分的組合物
EA201691741A1 (ru) Фармацевтическая композиция
MY182634A (en) Pharmaceutical containing sodium-dependent phosphate transporter inhibitor
EP3542797A4 (en) PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING DYRK-RELATED ILLNESSES USING PYRIDINE-BASED COMPOUNDS AS AN ACTIVE SUBSTANCE
MX2017005271A (es) Compuestos de nargenicina y sus usos como agentes antibacterianos.
EA201891848A1 (ru) Фармацевтическая композиция для применения в лечении фиброза
TN2015000058A1 (en) Salts of benzothiazolone compound as beta-2-adrenoceptor agonist
CO2019005512A2 (es) Fármaco terapéutico o fármaco profiláctico para la nefropatía diabética
UY35672A (es) Derivados de amino-metil-biarilo como inhibidores del factor de complemento d y usos de los mismos